426 related articles for article (PubMed ID: 23141475)
1. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab.
Schmidtko J; Peine S; El-Housseini Y; Pascual M; Meier P
Am J Kidney Dis; 2013 Feb; 61(2):289-99. PubMed ID: 23141475
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
Risitano AM; Marotta S
Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
[TBL] [Abstract][Full Text] [Related]
3. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
Legendre CM; Licht C; Muus P; Greenbaum LA; Babu S; Bedrosian C; Bingham C; Cohen DJ; Delmas Y; Douglas K; Eitner F; Feldkamp T; Fouque D; Furman RR; Gaber O; Herthelius M; Hourmant M; Karpman D; Lebranchu Y; Mariat C; Menne J; Moulin B; Nürnberger J; Ogawa M; Remuzzi G; Richard T; Sberro-Soussan R; Severino B; Sheerin NS; Trivelli A; Zimmerhackl LB; Goodship T; Loirat C
N Engl J Med; 2013 Jun; 368(23):2169-81. PubMed ID: 23738544
[TBL] [Abstract][Full Text] [Related]
4. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
Polito MG; Kirsztajn GM
J Bras Nefrol; 2010; 32(3):303-15. PubMed ID: 21103695
[TBL] [Abstract][Full Text] [Related]
5. The alternative pathway of complement and the thrombotic microangiopathies.
Teoh CW; Riedl M; Licht C
Transfus Apher Sci; 2016 Apr; 54(2):220-31. PubMed ID: 27160864
[TBL] [Abstract][Full Text] [Related]
6. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.
Fakhouri F; Frémeaux-Bacchi V; Loirat C
Eur J Intern Med; 2013 Sep; 24(6):492-5. PubMed ID: 23756030
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches.
Riedl M; Fakhouri F; Le Quintrec M; Noone DG; Jungraithmayr TC; Fremeaux-Bacchi V; Licht C
Semin Thromb Hemost; 2014 Jun; 40(4):444-64. PubMed ID: 24911558
[TBL] [Abstract][Full Text] [Related]
8. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.
Diamante Chiodini B; Davin JC; Corazza F; Khaldi K; Dahan K; Ismaili K; Adams B
Pediatrics; 2014 Jun; 133(6):e1764-8. PubMed ID: 24843055
[TBL] [Abstract][Full Text] [Related]
9. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
Fakhouri F; Delmas Y; Provot F; Barbet C; Karras A; Makdassi R; Courivaud C; Rifard K; Servais A; Allard C; Besson V; Cousin M; Châtelet V; Goujon JM; Coindre JP; Laurent G; Loirat C; Frémeaux-Bacchi V
Am J Kidney Dis; 2014 Jan; 63(1):40-8. PubMed ID: 24021908
[TBL] [Abstract][Full Text] [Related]
10. An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.
Sengul Samanci N; Ayer M; Ergen A; Ozturk S
Transfus Apher Sci; 2015 Jun; 52(3):314-6. PubMed ID: 25634788
[TBL] [Abstract][Full Text] [Related]
11. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome.
Christmann M; Hansen M; Bergmann C; Schwabe D; Brand J; Schneider W
Pediatrics; 2014 Jun; 133(6):e1759-63. PubMed ID: 24843059
[TBL] [Abstract][Full Text] [Related]
12. Clinical grand rounds: atypical hemolytic uremic syndrome.
Hodgkins KS; Bobrowski AE; Lane JC; Langman CB
Am J Nephrol; 2012; 35(5):394-400. PubMed ID: 22517061
[TBL] [Abstract][Full Text] [Related]
13. [Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches].
Kistler AD
Praxis (Bern 1994); 2016 Mar; 105(7):389-96. PubMed ID: 27005733
[TBL] [Abstract][Full Text] [Related]
14. Eculizumab therapy.
Cataland SR
Biol Blood Marrow Transplant; 2014 Apr; 20(4):438-9. PubMed ID: 24534107
[No Abstract] [Full Text] [Related]
15. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
Köse O; Zimmerhackl LB; Jungraithmayr T; Mache C; Nürnberger J
Semin Thromb Hemost; 2010 Sep; 36(6):669-72. PubMed ID: 20865644
[TBL] [Abstract][Full Text] [Related]
16. Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.
Rigothier C; Delmas Y; Roumenina LT; Contin-Bordes C; Lepreux S; Bridoux F; Goujon JM; Bachelet T; Touchard G; Frémeaux-Bacchi V; Combe C
Am J Kidney Dis; 2015 Aug; 66(2):331-6. PubMed ID: 26015278
[TBL] [Abstract][Full Text] [Related]
17. Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report.
Giordano M; Castellano G; Messina G; Divella C; Bellantuono R; Puteo F; Colella V; Depalo T; Gesualdo L
Pediatrics; 2012 Nov; 130(5):e1385-8. PubMed ID: 23027168
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab.
Wilson CH; Brown AL; White SA; Goodship TH; Sheerin NS; Manas DM
Transplantation; 2011 Oct; 92(8):e42-3. PubMed ID: 21989273
[No Abstract] [Full Text] [Related]
19. Eculizumab in secondary atypical haemolytic uraemic syndrome.
Cavero T; Rabasco C; López A; Román E; Ávila A; Sevillano Á; Huerta A; Rojas-Rivera J; Fuentes C; Blasco M; Jarque A; García A; Mendizabal S; Gavela E; Macía M; Quintana LF; María Romera A; Borrego J; Arjona E; Espinosa M; Portolés J; Gracia-Iguacel C; González-Parra E; Aljama P; Morales E; Cao M; Rodríguez de Córdoba S; Praga M
Nephrol Dial Transplant; 2017 Mar; 32(3):466-474. PubMed ID: 28339660
[TBL] [Abstract][Full Text] [Related]
20. [Eculizumab for the treatment of atypical hemolytic uremic syndrome: case report and revision of the literature].
Vaisbich MH; Henriques Ldos S; Watanabe A; Pereira LM; Metran CC; Malheiros DA; Modanez F; Silva JD; Vieira S; Macedo AC; Massarope B; Furusawa EA; Schvartsman BG
J Bras Nefrol; 2013; 35(3):237-41. PubMed ID: 24100744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
